{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":1,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":1,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"f8fc74a05c8b","filters":{"venue":"Reviews on Clinical Pharmacology and Drug Therapy"}},"results":[{"id":"W3165297872","doi":"10.17816/rcf19137-46","title":"Hypolipidemic drugs inhibiting the proprotein convertase of subtilisin/kexin type 9 (PCSK9): monoclonal antibodies, antisense oligonucleotides, small interfering ribonucleic acids","year":2021,"lang":"en","type":"article","venue":"Reviews on Clinical Pharmacology and Drug Therapy","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"PCSK9; Proprotein convertase; Kexin; Alirocumab; LDL receptor; Evolocumab; Pharmacology; Chemistry; Subtilisin; Monoclonal antibody; Cholesterol; Lipoprotein; Biochemistry; Antibody; Biology; Enzyme; Immunology","authors":[{"name":"Aleksey M. Chaulin","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.09023443268592535,"gpt":0.396901942384443,"spread":0.3066675096985177,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001602212,0.0003668,0.0003250526,0.0005011478,0.0001327298,0.0002685366,0.0001546965,0.000285095,0.001467428],"category_scores_gemma":[0.0001177138,0.0001004621,0.000243801,0.0002926061,0.0001991613,0.0002047951,0.0001977542,0.0007790048,0.0007070157],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002334813,"about_ca_system_score_gemma":0.0001481909,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003822444,"about_ca_topic_score_gemma":0.0005703301,"domain_scores_codex":[0.9999237,0.00001046921,0.00000957168,0.00001962674,0.00002449815,0.00001215326],"domain_scores_gemma":[0.9999707,0.000005937805,0.000009063921,0.000002273558,0.000006945468,0.000005181299],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001346806,0.0004484735,0.0005496209,0.001263611,0.00006482528,0.0002487294,0.00003916023,0.0002632002,0.6727438,0.001943792,0.003545908,0.3175421],"study_design_scores_gemma":[0.0009477822,0.005252048,0.007069956,0.0001651878,0.0002885463,0.002731443,0.00003926897,0.001233682,0.7436743,0.0009811899,0.2375728,0.00004365202],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.3693164,0.5688776,0.03263909,0.00305965,0.002293451,0.0004876931,0.001297475,0.001012972,0.02101573],"genre_scores_gemma":[0.7211393,0.2408227,0.01467108,0.001356396,0.0006820219,0.0004942225,0.001283887,0.00004996481,0.01950044],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.001467428,"threshold_uncertainty_score":0.004909039,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}